News

A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders.   Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February 08th 2022 - ArgoBio and Oncode Institute have...

A collaboration to develop a new class of small molecule for the treatment of Parkinson's disease and other indications.   Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company.   With €50M in capital, Argobio and its team of experienced entrepreneurs-in-residence...

Argobio is a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years   Argobio has 50 M€ of share capital committed by a syndicate of complementary and strategic investors with a shared goal to develop some of Europe’s most promising biotech innovations   Argobio will incubate early-stage,...